Unknown

Dataset Information

0

Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.


ABSTRACT: Most malignant tumors originate from epithelial tissues in which tight junctions mediate cell-cell interactions. Tight junction proteins, especially claudin-3 (CLDN3), are overexpressed in various cancers. Claudin-3 is exposed externally during tumorigenesis making it a potential biomarker and therapeutic target. However, the development of antibodies against specific CLDN proteins is difficult, because CLDNs are four-transmembrane domain proteins with high homology among CLDN family members and species. Here, we developed a human IgG1 monoclonal antibody (h4G3) against CLDN3 through scFv phage display using CLDN3-overexpressing stable cells and CLDN3-embedded lipoparticles as antigens. The h4G3 recognized the native conformation of human and mouse CLDN3 without cross-reactivity to other CLDNs. The binding kinetics of h4G3 demonstrated a sub-nanomolar affinity for CLDN3 expressed on the cell surface. The h4G3 showed antibody-dependent cellular cytotoxicity (ADCC) according to CLDN3 expression levels in various cancer cells by the activation of Fc?RIIIa (CD16a). The biodistribution of h4G3 was analyzed by intravenous injection of fluorescence-conjugated h4G3 which showed that it localized to the tumor site in xenograft mice bearing CLDN3-expressing tumors. These results indicate that h4G3 recognizes CLDN3 specifically, suggesting its value for cancer diagnosis, antibody-drug conjugates, and potentially as a chimeric antigen receptor (CAR) for CLDN3-expressing pan-carcinoma.

SUBMITTER: Yang H 

PROVIDER: S-EPMC7022679 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


Most malignant tumors originate from epithelial tissues in which tight junctions mediate cell-cell interactions. Tight junction proteins, especially claudin-3 (CLDN3), are overexpressed in various cancers. Claudin-3 is exposed externally during tumorigenesis making it a potential biomarker and therapeutic target. However, the development of antibodies against specific CLDN proteins is difficult, because CLDNs are four-transmembrane domain proteins with high homology among CLDN family members and  ...[more]

Similar Datasets

| S-EPMC4430301 | biostudies-literature
| S-EPMC9273722 | biostudies-literature
| S-EPMC6998413 | biostudies-literature
| S-EPMC5862916 | biostudies-literature
| S-EPMC4815051 | biostudies-literature
| S-EPMC6296366 | biostudies-literature
| S-EPMC6407165 | biostudies-literature
| S-EPMC10499537 | biostudies-literature
| S-EPMC3277898 | biostudies-other
| S-EPMC5490170 | biostudies-other